We identified three priority class A candidates—namely the SL interactors MDM2, TUBA1B (COAD/READ), and NDUFB5 (STAD) and the AL interactor CDK6 (in the pan-cancer dataset)—that encode targets of approved anticancer drugs or that are the focus of drug development efforts (Fig. 2D–F; Additional file 6: Table S5D) [36]. Here, MDM2 is linked to cancer.